- PureTech Health said subsidiary Vedanta Biosciences had released data showing that a product candidate had induced an anti-tumour response.

The treatment, VE800, is an orally-administered, live biotherapeutic product candidate in immuno-oncology.

Pre-clinical data showed it induced a systemic anti-tumour immune response both as a monotherapy and in combination with checkpoint inhibitors.

The data would be presented at the Society for Immunotherapy of Cancer's annual meeting on 8 November.

At 1:37pm: [LON:PRTC] PureTech Health Plc share price was +4.5p at 167p

Story provided by